Clinical Characteristics, Treatments, and Concurrent Mutations in Non-Small Cell Lung Cancer Patients With NF1 Mutations.

Autor: Bowman L; Eli Lilly and Company, Indianapolis, IN. Electronic address: bowman_lee_lb@lilly.com., Tiu R; Eli Lilly and Company, Indianapolis, IN., Smyth EN; Eli Lilly and Company, Indianapolis, IN., Willard MD; Eli Lilly and Company, Indianapolis, IN., Li L; Eli Lilly and Company, Indianapolis, IN., Beyrer J; Eli Lilly and Company, Indianapolis, IN., Han Y; Eli Lilly and Company, Indianapolis, IN., Singh A; Eli Lilly Services India Private Limited, Bangalore, India.
Jazyk: angličtina
Zdroj: Clinical lung cancer [Clin Lung Cancer] 2021 Jan; Vol. 22 (1), pp. 32-41.e1. Date of Electronic Publication: 2020 Sep 18.
DOI: 10.1016/j.cllc.2020.09.011
Abstrakt: Objectives: Metastatic non-small cell lung cancer (mNSCLC) is characterized by complex genomic alterations. NF1 mutations may confer distinct clinical characteristics within NSCLC, and real-world evidence on concurrent mutations, treatment patterns, and health outcomes is lacking.
Materials and Methods: This retrospective study was performed in patients with mNSCLC treated in the Flatiron Health network who underwent the FoundationOne tumor-sequencing. Anticancer therapies, concurrent mutations, real-world progression-free survival (rwPFS), and overall survival (OS) were assessed.
Results: Of the 1663 patients, 103 patients were identified with NF1 mutation. Concurrent mutations with Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (16.5%) and epidermal growth factor receptor fusion (6.8%) were the most frequent. In patients with NF1 mutation only (n = 57), 42% were women, 86% patients had smoking history, and 70% had non-squamous cell carcinoma type. Most (51%) of the patients with NF1 mutations received a single line of therapy versus other mutations and the overall treated population (44%). Platinum-based chemotherapy was the predominant first-line therapy, with programmed cell death-1/programmed cell death-ligand-1 inhibitors as subsequent lines of therapy. The NF1 mutation only group had numerically the shortest median rwPFS (82 days) than other mutation groups. Median OS for the NF1 mutation group in first, second, and third lines of therapy was 321, 498, and 210 days, respectively.
Conclusions: NF1 mutations confer distinct clinical characteristics in patients with mNSCLC. These patients may have different trajectories for progression and survival than seen for other mutations, experience less systemic therapy after first-line therapy, and may have shorter survival.
(Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: